scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
110 hedge funds and large institutions have $232M invested in scPharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 25 closing their positions.
478% more call options, than puts
Call options by funds: $5.69M | Put options by funds: $983K
59% more capital invested
Capital invested by funds: $146M → $232M (+$86.6M)
52% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 25
13% more funds holding
Funds holding: 97 → 110 (+13)
4.46% more ownership
Funds ownership: 72.42% → 76.88% (+4.5%)
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$14.8M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$11M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$9.73M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$7.08M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$4.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$14.7M |
| 2 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$7.23M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$7.02M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
-$4.57M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.78M |
SCPH Hedge Fund Activity: Q3 2025 in Review
110 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2025, worth a combined $232M — up 59% from $146M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SCPH positions and 25 closed out — a net gain of 13 holders — while 30 added to existing stakes and 28 trimmed.
The largest buyer was Weiss Asset Management, opening a new position worth an estimated $14.8M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $14.7M sold.
- 110 institutional investors held scPharmaceuticals (SCPH) as of Q3 2025, up from 97 in Q2 2025.
- Funds reported $232M of scPharmaceuticals stock for Q3 2025, up 59% quarter-over-quarter.
- 38 funds opened new scPharmaceuticals positions in Q3 2025 and 25 closed out, a net change of +13 holders.
- The largest scPharmaceuticals buyer in Q3 2025 was Weiss Asset Management, an estimated $14.8M added.
- The largest scPharmaceuticals seller in Q3 2025 was AIGH Capital Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q3 2025.